RegeneRx Biopharmaceuticals, Inc. Receives First Patent on Tß4’s Ability to Repair Lung Damage Resulting from Infections and Other Disorders

BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it has received an Australian patent for the use of Tß4, its derivatives, analogues and fragments, to repair pulmonary damage resulting from pulmonary microbial infections. The patent expires in 2023.

MORE ON THIS TOPIC